Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug development to commercial manufacturing. Laurus employs 6500+ people, including around 1050+ scientists at more than 11 facilities approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc.
Financial Results:
Laurus Labs Ltd reported Revenues for Q3FY25 of ₹1,415.00 Crores up from ₹1,195.00 Crore year on year, a rise of 18.41%.
Total Expenses for Q3FY25 of ₹1,294.00 Crores up from ₹1,163.00 Crores year on year, a rise of 11.26%.
Consolidated Net Profit of ₹93.00 Crores up 304.35% from ₹23.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹1.71, up 297.67% from ₹0.43 in the same quarter of the previous year.
![](data:image/svg+xml;charset=utf-8,<svg height="781px" width="640px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
